CodeBreak-lg.png

Amgen Oncology is testing a study drug to determine whether it has the potential to help people whose cancer contains the KRAS G12C mutation.

You can learn more about AMG 510, also known as sotorasib (the proposed generic name for AMG 510), and the CodeBreaK clinical trials on this website.

Explore CodeBreaK Clinical Trials

If you don’t know whether your cancer has the KRAS G12C mutation, ask your doctor if your cancer has been tested for genetic mutations. You can also contact Amgen for more information.

codebreak-image

A clinical trial for patients with non-small cell lung cancer whose cancer has the KRAS G12C mutation

Status
Recruiting

NEAREST LOCATION

15 miles

PHASE

Phase 3

CONDITION

Advanced non-small cell lung cancer (NSCLC)

STUDY DRUGS

sotorasib or docetaxel

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 1b

CONDITION

Advanced solid tumors

STUDY DRUGS

sotorasib and other anti-cancer medications

codebreak-image

A clinical trial for patients with advanced solid tumors that have the KRAS G12C mutation

Status
Recruiting

PHASE

Phase 1/2

CONDITION

Advanced solid tumors

STUDY DRUGS

sotorasib alone (most participants) or combined with another anti-cancer treatment (some participants)

If you are a physician or another healthcare professional interested in learning more about a CodeBreaK trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.